|
Variables
|
EVLP-LTx (n = 6)
|
Conventional-LTx (n = 15)
|
p-value
|
|---|
|
Weight (kg)
|
70.7 ± 19.3
|
59. 1 ± 7.9
|
0.060
|
|
Height (cm)
|
170.8 ± 11.8
|
169.9 ± 10.1
|
0.862
|
|
BMI
|
24.0 ± 5.3
|
20.5 ± 3.5
|
0.088
|
|
Male
|
3 (50%)
|
6 (40%)
|
0.523
|
|
Age (years)
|
54.1 ± 10.4
|
42.6 ± 14.8
|
0.100
|
|
Waiting list (days)
|
49.0 (7–174)
|
44 (4–389)
|
0.785
|
|
Pre-op Life support
|
|
Mechanical ventilation
|
0 (0.00%)
|
1 (6.66%)
|
0.714
|
|
ECMO
|
0 (0.00%)
|
1 (6.66%)
|
0.750
|
|
Major indication
| | |
0.407
|
|
COPD
|
3 (50.00%)
|
5 (33.33%)
| |
|
AAT1
|
1 (16.66%)
|
0 (0.00%)
| |
|
PH
|
0 (0.00%)
|
1 (6.66%)
| |
|
CF
|
1 (16.66%)
|
7 (46.66%)
| |
|
PF
|
1 (16.66%)
|
1 (6.66%)
| |
|
LAM
|
0 (0.00%)
|
1 (6.66%)
| |
|
Lab values
|
|
FVC (liters)
|
2.0 ± 0.4
|
1.0 ± 0.6
|
0.540
|
|
FEV1 (liters)
|
0.8 ± 10.4
|
54.1 ± 10.4
|
0.516
|
|
6MWT (%)
|
39.6 ± 21.4
|
45.9 ± 25.1
|
0.600
|
|
P-ALT (μkat/L)
|
0.41 ± 0.15
|
0.32 ± 10.4
|
0.181
|
|
P-AST (μkat/L)
|
0.46 ± 0.12
|
0.41 ± 0.11
|
0.443
|
|
P-creatinine (μmol/L)
|
64.4 ± 11.5
|
54.1 ± 15.8
|
0. 216
|
|
Tx-type
|
|
SLTx
|
0 (0%)
|
0 (0%)
| |
|
DLTx
|
6 (100%)
|
15 (100%)
| |
|
HLTx
|
0 (0%)
|
0 (0%)
| |
|
Re-LTx
|
0 (0%)
|
0 (0%)
| |
- Data are mean (SD), number (%), or median (range). The numbers are based on patients with available data. COPD, chronic obstructive pulmonary disease; AAT1, Alpha 1-antitrypsin deficiency; PH, pulmonary hypertension; CF, cystic fibrosis; PF, pulmonary fibrosis; LAM, Lymphangioleiomyomatosis; BMI, body-mass index; FVC, forced volume vital capacity; FEV1, forced volume expiratory capacity 1 s; 6MWT, 6-min walking test; AST, aspartate transaminase; ALT, alanine transaminase; SLTx, single-lung transplantation; DLTx, double-lung transplantation; HLTx, heart-lung transplantation; Re-LTx, re-lungtransplantation; ECMO, extracorporeal membrane oxygenation
